Laura Chico
Stock Analyst at Wedbush
(3.66)
# 614
Out of 5,182 analysts
259
Total ratings
45.05%
Success rate
7.26%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Neutral | $22 → $21 | $21.68 | -3.14% | 6 | Apr 2, 2026 | |
| PEPG PepGen | Maintains: Outperform | $9 → $5 | $1.73 | +189.02% | 14 | Apr 1, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $44 → $37 | $18.84 | +96.39% | 10 | Mar 31, 2026 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $12 → $13 | $4.79 | +171.40% | 6 | Mar 20, 2026 | |
| OVID Ovid Therapeutics | Maintains: Outperform | $5 → $7 | $2.20 | +218.18% | 3 | Mar 20, 2026 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $36 → $38 | $32.74 | +16.07% | 11 | Mar 18, 2026 | |
| EWTX Edgewise Therapeutics | Reiterates: Outperform | $32 | $33.33 | -3.99% | 12 | Mar 17, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $64 → $63 | $56.85 | +10.82% | 11 | Mar 16, 2026 | |
| MAZE Maze Therapeutics | Maintains: Outperform | $43 → $58 | $28.71 | +102.02% | 3 | Mar 16, 2026 | |
| SLDB Solid Biosciences | Maintains: Outperform | $14 → $17 | $7.49 | +126.97% | 5 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $103 | $86.00 | +19.77% | 14 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $15.49 | +54.94% | 4 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $6.56 | +113.41% | 2 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $18 | $40.41 | -55.46% | 15 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $6 → $1 | $0.37 | +170.27% | 7 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $5.94 | +219.87% | 16 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $95 → $130 | $310.38 | -58.12% | 12 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $25 | $22.45 | +11.36% | 15 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $149 → $151 | $131.60 | +14.74% | 11 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $178 → $187 | $177.34 | +5.45% | 20 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $30 | $20.65 | +45.28% | 10 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $40.86 | -19.24% | 9 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $30 | $28.41 | +5.60% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $30.44 | +5.12% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $9.02 | +99.56% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.96 | +76.77% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $88 | $8.42 | +945.75% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $11.23 | -55.48% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $55.50 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $4.37 | +14.42% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $9.80 | +1,415.31% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $10.17 | +6,979.65% | 1 | Jan 19, 2018 |
Alto Neuroscience
Apr 2, 2026
Maintains: Neutral
Price Target: $22 → $21
Current: $21.68
Upside: -3.14%
PepGen
Apr 1, 2026
Maintains: Outperform
Price Target: $9 → $5
Current: $1.73
Upside: +189.02%
Viridian Therapeutics
Mar 31, 2026
Maintains: Outperform
Price Target: $44 → $37
Current: $18.84
Upside: +96.39%
Larimar Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $12 → $13
Current: $4.79
Upside: +171.40%
Ovid Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $5 → $7
Current: $2.20
Upside: +218.18%
Stoke Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $36 → $38
Current: $32.74
Upside: +16.07%
Edgewise Therapeutics
Mar 17, 2026
Reiterates: Outperform
Price Target: $32
Current: $33.33
Upside: -3.99%
Xenon Pharmaceuticals
Mar 16, 2026
Maintains: Outperform
Price Target: $64 → $63
Current: $56.85
Upside: +10.82%
Maze Therapeutics
Mar 16, 2026
Maintains: Outperform
Price Target: $43 → $58
Current: $28.71
Upside: +102.02%
Solid Biosciences
Mar 12, 2026
Maintains: Outperform
Price Target: $14 → $17
Current: $7.49
Upside: +126.97%
Mar 12, 2026
Maintains: Outperform
Price Target: $80 → $103
Current: $86.00
Upside: +19.77%
Mar 9, 2026
Reiterates: Outperform
Price Target: $24
Current: $15.49
Upside: +54.94%
Mar 6, 2026
Maintains: Outperform
Price Target: $12 → $14
Current: $6.56
Upside: +113.41%
Feb 25, 2026
Maintains: Neutral
Price Target: $20 → $18
Current: $40.41
Upside: -55.46%
Feb 24, 2026
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.37
Upside: +170.27%
Feb 23, 2026
Reiterates: Outperform
Price Target: $19
Current: $5.94
Upside: +219.87%
Feb 20, 2026
Maintains: Underperform
Price Target: $95 → $130
Current: $310.38
Upside: -58.12%
Feb 17, 2026
Reiterates: Neutral
Price Target: $25
Current: $22.45
Upside: +11.36%
Feb 12, 2026
Maintains: Outperform
Price Target: $149 → $151
Current: $131.60
Upside: +14.74%
Feb 10, 2026
Maintains: Neutral
Price Target: $178 → $187
Current: $177.34
Upside: +5.45%
Dec 11, 2025
Maintains: Outperform
Price Target: $31 → $30
Current: $20.65
Upside: +45.28%
Dec 11, 2025
Maintains: Neutral
Price Target: $23 → $33
Current: $40.86
Upside: -19.24%
Nov 13, 2025
Maintains: Outperform
Price Target: $27 → $30
Current: $28.41
Upside: +5.60%
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $30.44
Upside: +5.12%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $9.02
Upside: +99.56%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.96
Upside: +76.77%
Apr 11, 2024
Maintains: Outperform
Price Target: $104 → $88
Current: $8.42
Upside: +945.75%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $11.23
Upside: -55.48%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $55.50
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $4.37
Upside: +14.42%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $9.80
Upside: +1,415.31%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $10.17
Upside: +6,979.65%